. 2021 Apr;12(Suppl 1):S5–S17. doi: 10.21037/jgo-20-129

Table 5. Patients with disease progression after surgery alone and HIPEC plus surgery.

Characteristics of disease progression	Group	N (%)	P value
Progression (with peritoneal dissemination)	Control	45 (81.8)	0.003
Progression (with peritoneal dissemination)	HIPEC	37 (54.4)	0.003
Metachronous peritoneal metastases*	Control	40 (72.7)	<0.001
Metachronous peritoneal metastases*	HIPEC	16 (23.5)	<0.001
Distant metastases
Liver metastases**	Control	3 (5.5)	0.018
Liver metastases**	HIPEC	14 (20.6)	0.018
Other metastases***	Control	2 (3.6)	0.186
Other metastases***	HIPEC	7 (10.3)	0.186

*, counting in patients with MPM and even with other distant metastases; **, counting in patients with metastases in the liver and other organs except for the peritoneum; ***, counting in patients with metastases in organs other than the peritoneum and the liver. HIPEC, hyperthermic intraperitoneal chemotherapy; MPM, metachronous peritoneal metastases.